阿柏西普治疗玻璃体黄斑牵引的逐步松解
Progressive Release of Vitreomacular Traction With Aflibercept.
作者信息
Schwartz Stephen G, Flynn Harry W
出版信息
Ophthalmic Surg Lasers Imaging Retina. 2016 May 1;47(5):477-81. doi: 10.3928/23258160-20160419-13.
A patient with combined diabetic macular edema (DME) and vitreomacular traction (VMT) was treated with a series of intravitreal aflibercept (Eylea; Regeneron, Tarrytown, NY) injections. The VMT progressively released during the course of the five intravitreal injections. This release may have been spontaneous, due to a nonspecific mechanical effect from the injections, or due to a pharmacologic effect from the aflibercept. While treating DME, anti-vascular endothelial growth factor agents may have an additional benefit in releasing VMT. [Ophthalmic Surg Lasers Imaging Retina. 2016;47:477-481.].
一名患有糖尿病性黄斑水肿（DME）合并玻璃体黄斑牵引（VMT）的患者接受了一系列玻璃体内注射阿柏西普（阿瓦斯汀；再生元公司，纽约州塔里敦）治疗。在五次玻璃体内注射过程中，VMT逐渐缓解。这种缓解可能是自发的，由于注射产生的非特异性机械效应，或者是由于阿柏西普的药理作用。在治疗DME时，抗血管内皮生长因子药物在缓解VMT方面可能有额外益处。[《眼科手术、激光与视网膜影像》。2016年；47:477 - 481。]
Zotero 插件